about
Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltrationAntimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemyAdvances in antibiotic therapy in the critically illFundamentals of aerosol therapy in critical careTherapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for?Ampicillin/sulbactam: its potential use in treating infections in critically ill patientsThe Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical TrialNebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis.Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted.Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) studyThe Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the EvidenceMeropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patientsMonte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients.Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancyIndividualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients.The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery.Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic.ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO.The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation.Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort studyDetermining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogramHow do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort studyVancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.Streamlined research funding using short proposals and accelerated peer review: an observational study.Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patientsAre standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.
P50
Q24620193-88FD845E-1879-42E4-ADA5-D148B4735F8AQ26739860-DE1213FE-A4AE-4BDD-9A41-C0BAEA7F3CF9Q26745677-1F22D3AB-F51C-448B-BAD8-FFF3CB161688Q26749328-1F4ACF51-77C6-4ED9-B63A-4C908A49BE11Q28068836-C0EFDA54-D704-4BE5-A647-3EF54F60620BQ28080607-FB56858A-741D-40C1-84E0-5BC772FF5F98Q28298626-8BD74A62-4035-42C1-9F42-86C1022F1D93Q28551575-CB37C4C7-38DC-4152-9109-ECCFBA4E480BQ30235511-CB6407FD-D657-44EB-AEA8-298A1F4C7904Q30828312-4E46C663-5124-49AB-8640-441EECB874D7Q30936281-3CCED13B-6B87-481A-904F-3051AA0F785DQ31032098-E649A6AB-3EB4-49A1-9FFB-6364BE82D37DQ31058057-94FAA2A9-9868-4A7C-AE03-6CEFAA700BA6Q31111978-F3F2452A-8B25-4662-9330-D37A29D5BF76Q33518061-83A4542E-7C3C-427F-9861-47A8C677727DQ33564316-E29270B5-BC40-4D73-A12A-7A4E10E50FF4Q33751132-111DAE20-7A21-4910-B927-88B1D19C6CDEQ33752635-AE379B85-ED47-4D09-B322-2AE9A97C4779Q33759273-850D0038-5131-4A83-9B54-7ABFBBDCED38Q33797868-66EE251F-7C2D-466F-AF89-79BD59BA6453Q33798203-82838CB1-91F1-4930-9412-C37BC976B59EQ33821972-0DFC33EF-2547-4947-93F6-CD8852CB33E2Q33824276-DC32912D-A388-4829-A4A4-99FF9C2050EBQ33826846-71142E8D-C656-4596-9CD1-01148EA1EB8CQ34108507-6EECC668-FD67-43D6-87C4-7B4295B8872EQ34274190-E35BBC42-B4C8-4B42-BFCE-6F2658386153Q34329290-82753A14-8AD0-4ECC-983D-C5FFF8D62988Q34494688-4BFE2175-A8B7-4C53-A99A-82F4764E3667Q34630847-C3AD7272-E3F3-44B6-AD2A-CE754BED7001Q34636783-02F80A0B-9F72-4BF3-8864-18B2A8460CDAQ34739945-79C53E85-B14A-4C3B-8AE6-7307929366DBQ34777837-7BF380E5-10DE-4C74-96AB-E73D754B3D00Q34894900-60965AC0-38C6-4091-94E4-696D012B3F58Q34996307-EE61A5F0-0025-4283-A5D2-B736E09B0EA5Q35004943-C105E270-CA9E-46D7-8BE3-89F16FA00CABQ35030247-B918F0E6-E71B-4DCB-890F-58886E251A2DQ35071561-6846E4F9-A25C-4F8D-BD40-CE6502AD69B7Q35076958-315184FD-158E-450E-ACD6-5692AC2E2BF7Q35124710-5C440386-1143-44DE-8767-7BBC8087E739Q35364423-55C108FE-79AF-4E4F-8954-7757401271BB
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jason A. Roberts
@ast
Jason A. Roberts
@en
Jason A. Roberts
@es
Jason A. Roberts
@nl
Jason A. Roberts
@sl
type
label
Jason A. Roberts
@ast
Jason A. Roberts
@en
Jason A. Roberts
@es
Jason A. Roberts
@nl
Jason A. Roberts
@sl
prefLabel
Jason A. Roberts
@ast
Jason A. Roberts
@en
Jason A. Roberts
@es
Jason A. Roberts
@nl
Jason A. Roberts
@sl
P1053
F-6272-2010
P106
P1153
35230697700
P21
P214
1270147665806660670000
P31
P3829
P496
0000-0001-6218-435X
P734
P735
P7859
lccn-n2017186318